The gut microbiota and inflammatory bowel disease - PubMed (original) (raw)

Review

The gut microbiota and inflammatory bowel disease

Katsuyoshi Matsuoka et al. Semin Immunopathol. 2015 Jan.

Abstract

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gut. Although the precise cause of IBD remains unknown, the most accepted hypothesis of IBD pathogenesis to date is that an aberrant immune response against the gut microbiota is triggered by environmental factors in a genetically susceptible host. The advancement of next-generation sequencing technology has enabled identification of various alterations of the gut microbiota composition in IBD. While some results related to dysbiosis in IBD are different between studies owing to variations of sample type, method of investigation, patient profiles, and medication, the most consistent observation in IBD is reduced bacterial diversity, a decrease of Firmicutes, and an increase of Proteobacteria. It has not yet been established how dysbiosis contributes to intestinal inflammation. Many of the known IBD susceptibility genes are associated with recognition and processing of bacteria, which is consistent with a role of the gut microbiota in the pathogenesis of IBD. A number of trials have shown that therapies correcting dysbiosis, including fecal microbiota transplantation and probiotics, are promising in IBD.

PubMed Disclaimer

Similar articles

• Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease.
  Yu CG, Huang Q. Yu CG, et al. J Dig Dis. 2013 Oct;14(10):513-7. doi: 10.1111/1751-2980.12087. J Dig Dis. 2013. PMID: 23848393 Review.
• Gut microbiota in the pathogenesis of inflammatory bowel disease.
  Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Nishida A, et al. Clin J Gastroenterol. 2018 Feb;11(1):1-10. doi: 10.1007/s12328-017-0813-5. Epub 2017 Dec 29. Clin J Gastroenterol. 2018. PMID: 29285689 Review.
• Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
  Eom T, Kim YS, Choi CH, Sadowsky MJ, Unno T. Eom T, et al. J Microbiol. 2018 Mar;56(3):189-198. doi: 10.1007/s12275-018-8049-8. Epub 2018 Feb 28. J Microbiol. 2018. PMID: 29492876 Review.
• Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease.
  Wang ZK, Yang YS, Chen Y, Yuan J, Sun G, Peng LH. Wang ZK, et al. World J Gastroenterol. 2014 Oct 28;20(40):14805-20. doi: 10.3748/wjg.v20.i40.14805. World J Gastroenterol. 2014. PMID: 25356041 Free PMC article. Review.
• [Gut microbiota and IBD].
  Seksik P. Seksik P. Gastroenterol Clin Biol. 2010 Sep;34 Suppl 1:S44-51. doi: 10.1016/S0399-8320(10)70020-8. Gastroenterol Clin Biol. 2010. PMID: 20889004 French.

Cited by

• Effect of Extracelluar Vesicles Derived from Akkermansia muciniphila on Intestinal Barrier in Colitis Mice.
  Zheng T, Hao H, Liu Q, Li J, Yao Y, Liu Y, Zhang T, Zhang Z, Yi H. Zheng T, et al. Nutrients. 2023 Nov 8;15(22):4722. doi: 10.3390/nu15224722. Nutrients. 2023. PMID: 38004116 Free PMC article.
• Protective Effects of Natural Antioxidants on Inflammatory Bowel Disease: Thymol and Its Pharmacological Properties.
  Liu Y, Yan H, Yu B, He J, Mao X, Yu J, Zheng P, Huang Z, Luo Y, Luo J, Wu A, Chen D. Liu Y, et al. Antioxidants (Basel). 2022 Sep 29;11(10):1947. doi: 10.3390/antiox11101947. Antioxidants (Basel). 2022. PMID: 36290669 Free PMC article. Review.
• The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood.
  Slattery J, MacFabe DF, Frye RE. Slattery J, et al. Clin Med Insights Pediatr. 2016 Oct 9;10:91-107. doi: 10.4137/CMPed.S38338. eCollection 2016. Clin Med Insights Pediatr. 2016. PMID: 27774001 Free PMC article. Review.
• Novel players in coeliac disease pathogenesis: role of the gut microbiota.
  Verdu EF, Galipeau HJ, Jabri B. Verdu EF, et al. Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):497-506. doi: 10.1038/nrgastro.2015.90. Epub 2015 Jun 9. Nat Rev Gastroenterol Hepatol. 2015. PMID: 26055247 Free PMC article. Review.
• An efficient system for intestinal on-site butyrate production using novel microbiome-derived esterases.
  Jung DH, Yong JH, Hwang W, Yoon MY, Yoon SS. Jung DH, et al. J Biol Eng. 2021 Mar 6;15(1):9. doi: 10.1186/s13036-021-00259-4. J Biol Eng. 2021. PMID: 33676548 Free PMC article.

References

1. 1. Rutgeerts P, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991;338:771–774. doi: 10.1016/0140-6736(91)90663-A. - DOI - PubMed
2. 1. Khan KJ, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661–673. doi: 10.1038/ajg.2011.72. - DOI - PubMed
3. 1. Ananthakrishnan AN, et al. Strategies for the prevention of postoperative recurrence in Crohn’s disease: results of a decision analysis. Am J Gastroenterol. 2011;106:2009–2017. doi: 10.1038/ajg.2011.237. - DOI - PubMed
4. 1. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124. doi: 10.1038/nature11582. - DOI - PMC - PubMed
5. 1. Eckburg PB, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635–1638. doi: 10.1126/science.1110591. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Springer

• Other Literature Sources

  • scite Smart Citations